The Latest Breaking News from Pfizer Inc.

Moderna requests FDA approval for fourth COVID shot for adults

Moderna Inc. has filed for U.S. regulatory clearance of a second COVID-19 booster shot for all adults, covering significantly more people than Pfizer Inc. and BioNTech SE’s request earlier this week for a more limited emergency authorization for those over 65.

Tribune News Service · Mar 18, 2022

Pfizer asks FDA to clear another booster for older adults

Pfizer Inc. said it has asked U.S. regulators for clearance of an additional COVID-19 booster shot for seniors, in a bid to protect vulnerable adults as immunity provided by the first three doses wanes.

Tribune News Service · Mar 16, 2022

Pfizer halts trials in Russia but will continue to supply drugs

Pfizer Inc. said it would no longer start new clinical trials in Russia and that it would donate all profits from its subsidiary in the country to Ukraine relief causes.

Tribune News Service · Mar 14, 2022

Japan OKs Pfizer COVID-19 oral pills amid surging infections

Japan has granted fast-track approval to U.S. drug maker Pfizer Inc.’s COVID-19 pill as the country struggles to slow fast-spreading omicron infections

The Independent UK · Feb 10, 2022

5 Stocks To Watch For February 8, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects Pfizer Inc. (NYSE: PFE) to report quarterly earnings at $0.87 per share on revenue of $24.20 billion before the opening bell. Pfizer shares rose 1.7% to $54.10 in after-hours trading.

Benzinga · Feb 8, 2022

Pfizer seeking FDA clearance for COVID shot in children under 5

Pfizer Inc. and partner BioNTech SE have begun submitting data to U.S. regulators for authorization of their COVID-19 vaccine in children 6 months to 4 years old, according to people familiar with the matter, hastening an effort to get shots to younger kids after the omicron wave caused pediatric infections…

Tribune News Service · Feb 1, 2022

Study: Antibody levels 2.4 times higher after COVID-19 booster

People who had received a third dose of Pfizer Inc.'s COVID-19 vaccine had 2.4 times the level of antibodies compared to when they received their second dose, according to a team of Japanese researchers.

The Japan News/Yomiuri · Jan 28, 2022

Pfizer, BioNTech begin study of omicron-specific COVID vaccine

Pfizer Inc. said it is starting a study of a COVID-19 vaccine that targets the omicron variant, exploring its use in previously vaccinated younger and middle-aged adults as well as those who haven’t received another coronavirus shot.

Tribune News Service · Jan 25, 2022

Children aged 5-11 OK'd to be vaccinated in Japan

The Health, Labor and Welfare Ministry on Friday gave fast-track approval to the inoculation of children aged 5 to 11 with a coronavirus vaccine from U.S. pharmaceutical firm Pfizer Inc.

The Japan News/Yomiuri · Jan 21, 2022

Early omicron breakthroughs show mRNA vaccines’ weakness

Booster shots with messenger RNA vaccines such as those made by Pfizer Inc. and BioNTech SE failed to block omicron in a study of some of the first documented breakthrough cases caused by the highly contagious variant.

Tribune News Service · Jan 19, 2022